Current Controversies for the Therapy of HER2-positive metastatic Breast Cancer

被引:0
|
作者
Harbeck, Nadia [1 ]
机构
[1] Leiterin Brustzentrums Univ Munchen LMU, Munich, Germany
关键词
D O I
10.1159/000480445
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:269 / 271
页数:3
相关论文
共 50 条
  • [1] Therapy for HER2-Positive Metastatic Breast Cancer
    Dekker, Tim J. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25):
  • [2] Therapy for HER2-Positive Metastatic Breast Cancer REPLY
    Winer, Eric P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25):
  • [3] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Systemic therapy for metastatic HER2-positive breast cancer
    Bredin, Philip
    Walshe, Janice M.
    Denduluri, Neelima
    SEMINARS IN ONCOLOGY, 2020, 47 (05) : 259 - 269
  • [6] Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
    Vega Cano, Kreina Sharela
    Marmolejo Castaneda, David Humberto
    Escriva-de-Romani, Santiago
    Saura, Cristina
    CANCERS, 2023, 15 (01)
  • [7] Current and Future Management of HER2-Positive Metastatic Breast Cancer
    Martinez-Saez, Olga
    Prat, Aleix
    JCO ONCOLOGY PRACTICE, 2021, 17 (10) : 594 - +
  • [8] Current and emerging therapies of HER2-positive metastatic breast cancer
    Hernandez-Blanquisett, Abraham
    Touya, Diego
    Strasser-Weippl, Kathrin
    Ruiz, Rossana
    St Louis, Jessica
    Goss, Paul
    BREAST, 2016, 29 : 170 - 177
  • [9] Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
    Dempsey, Naomi
    Sandoval, Ana
    Mahtani, Reshma
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (09) : 1120 - 1137
  • [10] Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
    Naomi Dempsey
    Ana Sandoval
    Reshma Mahtani
    Current Treatment Options in Oncology, 2023, 24 (9) : 1120 - 1137